UBS Group Begins Coverage on Kura Oncology (NASDAQ:KURA)

UBS Group began coverage on shares of Kura Oncology (NASDAQ:KURA) in a report released on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $27.00 price objective on the stock.

A number of other brokerages have also weighed in on KURA. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and reduced their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. JMP Securities reiterated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Monday, August 12th. Finally, Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Price Performance

NASDAQ:KURA opened at $17.51 on Thursday. Kura Oncology has a 12-month low of $7.52 and a 12-month high of $24.17. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -7.85 and a beta of 0.84. The company’s 50-day moving average is $19.34 and its two-hundred day moving average is $20.09. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter last year, the business posted ($0.53) earnings per share. Kura Oncology’s revenue was up .0% compared to the same quarter last year. Research analysts expect that Kura Oncology will post -2.46 EPS for the current year.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in Kura Oncology during the third quarter valued at approximately $25,000. ProShare Advisors LLC increased its position in shares of Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after acquiring an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC raised its stake in shares of Kura Oncology by 2.4% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after acquiring an additional 1,673 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its position in Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.